Prominent Italian Oncology Center Chooses IntraOp Medical's Mobetron for Cancer Treatment.

Italy Leads Europe in Intraoperative Electron Radiation Therapy with Fourth Hospital Implementing Mobetron

SUNNYVALE, Calif. -- IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that it received an order to deliver one Mobetron to Centro di Riferimento Oncologico (CRO) in Aviano, Italy. CRO is the fourth Italian hospital to have a Mobetron and the 23rd Mobetron ordered worldwide. Mobetron is an FDA-approved, easily transportable electron-beam device designed for Intraoperative Electron Radiation Therapy (IOERT), or the direct application of radiation to a tumor while a patient is undergoing cancer surgery.

CRO currently performs IOERT by transporting the patient in the middle of surgery from the operating room to the radiation therapy department to receive treatment. The hospital currently treats primarily sarcoma and pancreatic cancer patients in their IOERT program. Mobetron will be located in the operating room and will allow CRO to treat a variety of other types of cancer, including IOERT for early-stage breast cancer.

Mobetron was a donation to CRO from a group of local private entrepreneurs that, with the help of GOCNE (Gruppo Oncologico Cooperativo Nord Est) and Fondazione CRUP, were able to acquire the advanced IOERT technology. CRO is one of best scientific cancer research centers in Italy and is on the frontlines in the war against cancer.

Professor Mauro Trovo, director of the radiation oncology department at the CRO, said, "I am very glad for this great opportunity that we received. This will be very important for the future development of IOERT, not only at our institute, but also in Italy. The CRO already performs IOERT with a conventional linear accelerator and this donation offered us Mobetron, which we consider to be the best IOERT-dedicated treatment unit available at present."

"We have already started planning work in order to be able to use Mobetron at full throttle as soon as possible after the unit is delivered. With Mobetron we will be able to promote further clinical studies to make IOERT the standard of care for other tumors, not just for breast cancer surgery, like it is already going to be," said Dr. Antonino De Paoli, radiation oncologist coordinator of the IOERT program at the CRO.

Ernesto Lanzotti, general director of MD51, Intraop's distributor in Italy, added, "CRO is a very important addition to our IOERT program in Italy. I expect CRO to continue to be an active promoter and participant in the many new IOERT clinical studies that are being developed by the International Society of IORT Europe, such as IOERT for lung, prostate and breast. They join a growing number of cancer centers that recognize the importance of integrating IOERT into their cancer program and have selected Mobetron as their equipment of choice."

About Centro di Riferimento Oncologico

Centro di Riferimento Oncologico is a teaching, research and treatment hospital in northern Italy. CRO is one of the few hospitals in Italy that has been given the status of Istituto per la Ricerca e la Cura del Cancro a carattere Scientifico ("IRCCS"-Institute for Research in the Cure of Cancer and Scientific Study). The Hospital Center treats more than 3,000 cancer patients per year and has several publications in the field of radiation and surgical oncology and IOERT.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.